Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Şendur · SciRah

Researcher profile · Semantic Scholar

M. Şendur

Share profile

M. Şendur — researcher profile on SciRah

h-index: 24
Works: 256
Citations: 2,307

Most-cited papers

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
B. Cho, Shun Lu, E. Felip, A. Spira +53 more
2024New England Journal of Medicine403 citations Open access
Semantic Scholar
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
L. Paz-Ares, Hossein Borghaei, Stephen V. Liu, S. Peters +25 more
2025The Lancet93 citations
Semantic Scholar
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study
E. Yekedüz, D. Tural, İ. Ertürk, S. Karakaya +12 more
2022Journal of Cancer Research and Clinical Oncology32 citations Open access
Semantic Scholar
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study
N. Akdeniz, M. Kaplan, D. Uncu, M. Inanc +16 more
2021International Journal of Colorectal Disease28 citations Open access
Semantic Scholar
Predicting hepatocellular carcinoma survival with artificial intelligence
Ismet Seven, D. Bayram, Hilal Arslan, F. T. Köş +5 more
2025Scientific Reports24 citations Open access
Semantic Scholar
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
C. Karaçin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç +82 more
2023BMC Cancer23 citations Open access
Semantic Scholar
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
D. Tural, Ö. Ölmez, A. Sümbül, N. Ozhan +33 more
2021International Journal of Clinical Oncology20 citations
Semantic Scholar
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
K. B. Yücel, E. Yekedüz, S. Karakaya, D. Tural +15 more
2022Scientific Reports19 citations Open access
Semantic Scholar
The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
D. Guven, R. Acar, E. Yekeduz, I. Bilgetekin +9 more
2021Current Problems in Cancer19 citations
Semantic Scholar
Understanding of Clinical Trials Among Patients With Cancer and Their Relatives
Pınar Kubilay Tolunay, C. Erol, S. Kahraman, Seher Yıldız Tacar +9 more
2025JAMA Network Open14 citations Open access
Semantic Scholar
Lung Cancer in Turkey.
A. Cangir, P. Yumuk, S. Sak, S. Akyürek +16 more
2022Journal of Thoracic Oncology14 citations Open access
Semantic Scholar
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy
Yi-Long Wu, Lin Wu, N. Bi, T. Çil +16 more
2025Journal of Hematology & Oncology13 citations Open access
Semantic Scholar
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
S. Kahraman, S. Karakaya, Muhammed Ali Kaplan, S. Goksu +43 more
2024Scientific Reports13 citations Open access
Semantic Scholar
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Mustafa Gürbüz, Yasin Kutlu, E. Akkuş, E. Köksoy +35 more
2022Journal of Cancer Research and Clinical Oncology13 citations Open access
Semantic Scholar
Major and minor salivary gland cancers: A multicenter retrospective study
M. B. Hacıoğlu, B. Erdoğan, M. Bardakçı, E. Algın +55 more
2023Head and Neck11 citations Open access
Semantic Scholar
Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and HIPEC Improves Survival in Peritoneal Metastatic Gastric Cancer
S. Esen, Y. M. Ozgun, Denizcan Hasturk, G. Ucar +3 more
2023Oncology10 citations
Semantic Scholar
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
Çağlar Ünal, A. Azizy, Senem Karabulut, D. Taştekin +60 more
2023The Oncologist9 citations Open access
Semantic Scholar
“Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?
C. Karaçin, R. Acar, O. Bal, T. Eren +6 more
2021Supportive Care in Cancer9 citations Open access
Semantic Scholar
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
H. Bolek, Omer Faruk Kuzu, Elif Sertesen Çamöz, Saadet Sim +14 more
2025Clinical and Translational Oncology8 citations Open access
Semantic Scholar
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)
C. Erol, A. Sakin, Tuğba Başoğlu, Ercan Özden +45 more
2022Turkish Journal of Medical Sciences8 citations Open access
Semantic Scholar
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
M. Mıldanoğlu, Yasin Kutlu, Onur Baş, B. Koylu +18 more
2025Scientific Reports7 citations Open access
Semantic Scholar
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
S. Kahraman, E. Erul, O. Gumusay, D. Guven +66 more
2025Clinical Breast Cancer6 citations Open access
Semantic Scholar
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
S. Kahraman, M. Hızal, B. Demirel, D. Guven +34 more
2024BMC Cancer6 citations Open access
Semantic Scholar
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Carlos Rojas, Ferry Eskens, F. Ghiringhelli, M. Özgüroğlu +16 more
2024Journal of Clinical Oncology6 citations
Semantic Scholar
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy
Yusuf Ilhan, G. Ucar, M. Başer, Halil Goksel Guzel +19 more
2024Expert Opinion on Pharmacotherapy5 citations
Semantic Scholar
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
Yasin Kutlu, Shute Ailia Dae, F. Yılmaz, D. Erdem +18 more
2024Cancers5 citations Open access
Semantic Scholar
The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas
D. Aydın, U. Kefeli, M. Ozcelik, G. Erdem +5 more
2023Medicina5 citations Open access
Semantic Scholar
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
A. Akyıldız, D. Guven, A. Ozluk, Rashad Ismayilov +30 more
2023Medicine5 citations Open access
Semantic Scholar
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
C. Karaçin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç +82 more
2023BMC Cancer5 citations Open access
Semantic Scholar
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
M. Hızal, B. Bilgin, N. Paksoy, M. Atcı +34 more
2022Journal of Cancer Research and Clinical Oncology5 citations Open access
Semantic Scholar
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
B. Bilgin, M. Şendur, Ş. Yücel, Emir Çelik +33 more
2021Journal of Cancer Research and Clinical Oncology5 citations Open access
Semantic Scholar
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study
T. K. Şahin, Fatih Atalah, B. Koylu, Ahmet Oruç +37 more
2025Frontiers in Immunology4 citations
Semantic Scholar
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
E. Yekedüz, M. Özbay, Dilek Çağlayan, Atila Yıldırım +13 more
2022European Journal of Clinical Pharmacology4 citations Open access
Semantic Scholar
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
T. Telli, A. Tatlı, Özkan Alan, Gül Keskin +32 more
2025Clinical Lung Cancer3 citations
Semantic Scholar
Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group
S. Tunbekici, Gökhan Şahin, Sercan Ön, Ahmet Oruç +72 more
2025International Journal of Cancer3 citations
Semantic Scholar
Is fibroblast growth factor 11 (FGF11) a predictive marker for breast cancer?
Selin Aktürk Esen, Ş. Karabulut, Muge Buyukaksoy, Gulnaz Kurt Cevik +5 more
2024Medicine3 citations Open access
Semantic Scholar
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
S. Sekmek, S. Ö. Özsan Çelebi, D. Bayram, C. Erol +22 more
2024Scientific Reports3 citations Open access
Semantic Scholar
Clinical features and prognostic factors in thymoma and thymic carcinoma
D. Bayram, S. Sekmek, M. Kayaalp, M. Bardakçı +8 more
2024Indian Journal of Thoracic and Cardiovascular Surgery3 citations Open access
Semantic Scholar
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically
M. Bardakçı, Derya Demirtaş Esmer, E. Hafızoğlu, Ş. Yaslıkaya +15 more
2023Oncology3 citations Open access
Semantic Scholar
RETRACTED ARTICLE: Tarsoconjunctival Granulation Tissue Formation Associated with EGFR Inhibitors
Ferhan Guler, N. Yuksel, S. Kahraman, M. Şendur
2022Oncology and Therapy3 citations Open access
Semantic Scholar
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
Mustafa Gürbüz, S. Kılıçkap, A. Bilici, N. Karadurmuş +22 more
2022Medicine3 citations Open access
Semantic Scholar
Can the host immune response against SARS-CoV2 also cause an anticancer effect?
S. Kahraman, M. Akinci, M. Şendur, B. Yalcin
2021Medical Oncology3 citations Open access
Semantic Scholar
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
M. Hızal, B. Bilgin, N. Paksoy, Özgür Açıkgöz +29 more
2021Journal of Cancer Research and Clinical Oncology3 citations Open access
Semantic Scholar
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer
F. Ceylan, S. C. Efil, Didem Şener Dede, A. Tenekeci +8 more
2025Expert Review of Anticancer Therapy2 citations
Semantic Scholar
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study.
Selin Akturk Esen, Ismet Seven, Gonca Akdere Ates, Rumeysa Çolak +18 more
2025Anti-Cancer Drugs2 citations Open access
Semantic Scholar
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma
Omer Faruk Kuzu, H. Bolek, Elif Sertesen Çamöz, H. Karakaş +14 more
2025BMC Cancer2 citations Open access
Semantic Scholar
Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience
O. Baş, B. K. İnci, Imdat Eroglu, S. C. Efil +8 more
2025BMC Cancer2 citations Open access
Semantic Scholar
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium
H. Bolek, Omer Faruk Kuzu, Elif Sertesen Çamöz, Saadet Sim +14 more
2025Cancer Communications2 citations Open access
Semantic Scholar
223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study
S. Kahraman, E. Erul, O. Gumusay, D. Guven +16 more
2024ESMO Open2 citations Open access
Semantic Scholar
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG).
H. A. Yaşar, B. Aktaş, G. Ucar, S. Goksu +29 more
2024Clinical Genitourinary Cancer2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Karadurmuş×17
Invite
N. Karadurmuş — researcher profile on SciRah
C. Erol×14
Invite
C. Erol — researcher profile on SciRah
S. Kılıçkap×14
Invite
S. Kılıçkap — researcher profile on SciRah
S. Kahraman×13
Invite
S. Kahraman — researcher profile on SciRah

×13

Invite

T. Şakalar — researcher profile on SciRah

Invite

N. Paksoy — researcher profile on SciRah

F. Selçukbiricik×11

Invite

F. Selçukbiricik — researcher profile on SciRah

Invite

A. Sakin — researcher profile on SciRah

Invite

A. Tatlı — researcher profile on SciRah

Invite

Y. Ergun — researcher profile on SciRah

Invite

C. Karaçin — researcher profile on SciRah

Invite

B. Gulbagci — researcher profile on SciRah